Rasbelon 1.5mg Injection

Rasbelon 1.5mg Injection is an antihyperuricemic drug belonging to the category of uricolytic agent, containing the active ingredient Rasburicase. It is used in the treatment of acute hyperuricemia in patients receiving chemotherapy. When cancer cells break down, they can release large amounts of uric acid into the bloodstream. This can cause hyperuricemia, which can lead to kidney damage and other health problems. Also, this medicine can be used to prevent or treat hyperuricemia in patients with tumor lysis syndrome .

In patients with G6PD deficiency, rasburicase can trigger hemolysis by generating reactive oxygen species that damage red blood cells. As a result, Rasbelon 1.5mg Injection is generally contraindicated in patients with G6PD deficiency. If you are diagnosed with this deficiency, inform your physician before taking this medicine because you will be more likely to experience severe haemolytic anaemia or methemoglobinemia.

Children who are undergoing chemotherapy for leukaemia, lymphoma, or solid tumor malignancies are at risk for developing hyperuricemia, which can lead to kidney damage, seizures, and other complications. This drug helps to treat hyperuricemia by rapidly reducing the levels of uric acid in the blood. It is important to closely monitor children who are receiving Rasbelon Injection for any signs of allergic reactions, hemolysis , or any other side effects. Talk with your healthcare provider if you have kidney or liver disease, vision problems and lung problems.